Editas Medicine, Inc. (EDIT)

Over the past six months, Editas Medicine's stock price has been impacted by several events. These include the Q3 2025, Q4 2025, and Q1 2026 earnings releases, the presentation of new preclinical data for EDIT-401, and the U.S. Patent and Trademark Office reaffirming its decision in favor of the Broad Institute in a CRISPR/Cas9 interference. Editas Medicine's stock price increased by 51.7% from the beginning of 2026 to May 2026, and by 94.81% over the past year.

The demand for Editas Medicine's products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by the prevalence of the diseases it aims to treat and the progress and success of its clinical trials and regulatory approvals.

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines using CRISPR gene editing technologies. The company operates in the Healthcare sector, specifically in Biotechnology, Genome Engineering, and Pharmaceutical industries, utilizing CRISPR/Cas9 and CRISPR/Cas12a platforms to correct disease-causing genetic mutations. Its major product pipeline candidates include EDIT-101 for Leber congenital amaurosis type 10, EDIT-301 for severe hematologic diseases, EDIT-401 for hyperlipidemia and atherosclerotic cardiovascular disease, and oncology programs focused on modifying immune cells to enhance anti-tumor activity.

Editas Medicine's primary operational footprint is centered in the United States, with headquarters in Cambridge, Massachusetts, and additional facilities in Boulder, Colorado. While its direct office presence is US-based, the company's reach extends globally through its clinical trials and collaborations.

Editas Medicine has generally maintained a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.57. There have been no major C-level departures, and the company has strategically strengthened its executive leadership team. Investor sentiment in some forums has shown optimism regarding the stock's potential, and no specific events negatively impacting Editas Medicine's brand reputation in the past year were found.

Editas Medicine, Inc. has a diverse ownership structure. Individual investors hold the largest stake, possessing 55% of the company's shares, while institutions collectively hold 45% of the shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Renaissance Technologies Llc, among others.